Intrapulmonic Cavity or Necrosis on Baseline CT Scan Serves as an Efficacy Predictor of Anti-PD-(L)1 Inhibitor in Advanced Lung Squamous Cell Carcinoma

References

• Remon J, Passiglia F, Ahn MJ, et al. Immune checkpoint inhibitors in thoracic malignancies: review of the existing evidence by an IASLC expert panel and recommendations. J Thorac Oncol. 2020;15(6):914–947.32179179
   PubMed Web of Science ®Google Scholar
• Lantuejoul S, Sound-Tsao M, Cooper WA, et al. PD-L1 testing for lung cancer in 2019: perspective from the IASLC Pathology Committee. J Thorac Oncol. 2020;15(4):499–519. doi:10.1016/j.jtho.2019.12.10731870882
   PubMed Web of Science ®Google Scholar
• Mok TSK, Wu Y, Kudaba I, et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, Phase 3 trial. Lancet. 2019;393(10183):1819–1830. doi:10.1016/S0140-6736(18)32409-730955977
   PubMed Web of Science ®Google Scholar
• Leighl NB, Hellmann MD, Hui R, et al. Pembrolizumab in patients with advanced non-small-cell lung cancer (KEYNOTE-001): 3-year results from an open-label, Phase 1 study. Lancet Respir Med. 2019;7(4):347–357. doi:10.1016/S2213-2600(18)30500-930876831
   PubMed Web of Science ®Google Scholar
• Reck M, Rodríguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1–positive non–small-cell lung cancer. New Engl J Med. 2016;375(19):1823–1833. doi:10.1056/NEJMoa160677427718847
   PubMed Web of Science ®Google Scholar
• Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372(21):2018–2028. doi:10.1056/NEJMoa150182425891174
   PubMed Web of Science ®Google Scholar
• Osipov A, Lim SJ, Popovic A, et al. Tumor mutational burden, toxicity, and response of immune checkpoint inhibitors targeting PD(L)1, CTLA-4, and combination: a meta-regression analysis. Clin Cancer Res. 2020;26(18):4842–4851. doi:10.1158/1078-0432.CCR-20-045832586938
   PubMed Web of Science ®Google Scholar
• Sha D, Jin Z, Budczies J, et al. Tumor mutational burden as a predictive biomarker in solid tumors. Cancer Discov. 2020;10(12):1808–1825. doi:10.1158/2159-8290.CD-20-052233139244
   PubMed Web of Science ®Google Scholar
• Marabelle A, Le DT, Ascierto PA, et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: results from the Phase II KEYNOTE-158 Study. J Clin Oncol. 2020;38(1):1–10. doi:10.1200/JCO.19.0210531682550
   PubMed Web of Science ®Google Scholar
• Petrelli F, Ghidini M, Ghidini A, et al. Outcomes following immune checkpoint inhibitor treatment of patients with microsatellite instability-high cancers: a systematic review and meta-analysis. JAMA Oncol. 2020;6(7):1068. doi:10.1001/jamaoncol.2020.104632407439
   PubMed Web of Science ®Google Scholar
• Overman MJ, McDermott R, Leach JL, et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, Phase 2 study. Lancet Oncol. 2017;18(9):1182–1191. doi:10.1016/S1470-2045(17)30422-928734759
   PubMed Web of Science ®Google Scholar
• Redman MW, Papadimitrakopoulou VA, Minichiello K, et al. Biomarker-driven therapies for previously treated squamous non-small-cell lung cancer (Lung-MAP SWOG S1400): a biomarker-driven master protocol. Lancet Oncol. 2020;21(12):1589–1601. doi:10.1016/S1470-2045(20)30475-733125909
   PubMed Web of Science ®Google Scholar
• Doroshow D, Wei W, Zugazagoitia J, et al. PD-L1 tumor proportion score and clinical benefit from first-line pembrolizumab in patients with advanced nonsquamous versus squamous non-small cell lung cancer (NSCLC). J Clin Oncol. 2020;38:9539. doi:10.1200/JCO.2020.38.15_suppl.9539
   Web of Science ®Google Scholar
• Liu Z, Jiao D. Necroptosis, tumor necrosis and tumorigenesis. Cell Stress. 2019;4(1):1–8. doi:10.15698/cst2020.01.20831922095
   PubMed Web of Science ®Google Scholar
• Green DR. The coming decade of cell death research: five riddles. Cell. 2019;177(5):1094–1107. doi:10.1016/j.cell.2019.04.02431100266
   PubMed Web of Science ®Google Scholar
• Brown JM, Wilson WR. Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer. 2004;4(6):437–447. doi:10.1038/nrc136715170446
   PubMed Web of Science ®Google Scholar
• Gatenby RA, Gillies RJ. Why do cancers have high aerobic glycolysis? Nat Rev Cancer. 2004;4(11):891–899. doi:10.1038/nrc147815516961
   PubMed Web of Science ®Google Scholar
• Lotfi R, Kaltenmeier C, Lotze MT, et al. Until death do us part: necrosis and oxidation promote the tumor microenvironment. Transfus Med Hemother. 2016;43(2):120–132. doi:10.1159/00044494127226794
   PubMed Web of Science ®Google Scholar
• Werfel TA, Elion DL, Rahman B, et al. Treatment-induced tumor cell apoptosis and secondary necrosis drive tumor progression in the residual tumor microenvironment through MerTK and IDO1. Cancer Res. 2019;79(1):171–182. doi:10.1158/0008-5472.CAN-18-110630413412
   PubMed Web of Science ®Google Scholar
• Hijaze N, Ledersnaider M, Simanovich E, et al. Inducing regulated necrosis and shifting macrophage polarization with anti-EMMPRIN antibody (161-pAb) and complement factors. J Leukoc Biol. 2020. doi:10.1002/JLB.3A0520-333R
   PubMed Web of Science ®Google Scholar
• Atanasov G, Dino K, Schierle K, et al. Angiogenic inflammation and formation of necrosis in the tumor microenvironment influence patient survival after radical surgery for de novo hepatocellular carcinoma in non-cirrhosis. World J Surg Oncol. 2019;17(1):217. doi:10.1186/s12957-019-1756-831830991
   PubMed Web of Science ®Google Scholar
• Eil R, Vodnala SK, Clever D, et al. Ionic immune suppression within the tumour microenvironment limits T cell effector function. Nature. 2016;537(7621):539–543. doi:10.1038/nature1936427626381
   PubMed Web of Science ®Google Scholar
• Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–247. doi:10.1016/j.ejca.2008.10.02619097774
   PubMed Web of Science ®Google Scholar
• Hansell DM, Bankier AA, MacMahon H, et al. Fleischner Society: glossary of terms for thoracic imaging. Radiology. 2008;246(3):697–722. doi:10.1148/radiol.246207071218195376
   PubMed Web of Science ®Google Scholar
• Reiniger L, Téglási V, Pipek O, et al. Tumor necrosis correlates with PD-L1 and PD-1 expression in lung adenocarcinoma. Acta Oncol. 2019;58(8):1087–1094. doi:10.1080/0284186X.2019.159857531002007
   PubMed Web of Science ®Google Scholar
• Chang YL, Yang CY, Lin MW, et al. High co-expression of PD-L1 and HIF-1α correlates with tumour necrosis in pulmonary pleomorphic carcinoma. Eur J Cancer. 2016;60:125–135. doi:10.1016/j.ejca.2016.03.01227107327
   PubMed Web of Science ®Google Scholar
• Chen TC, Wu CT, Wang CP, et al. Associations among pretreatment tumor necrosis and the expression of HIF-1α and PD-L1 in advanced oral squamous cell carcinoma and the prognostic impact thereof. Oral Oncol. 2015;51(11):1004–1010. doi:10.1016/j.oraloncology.2015.08.01126365985
   PubMed Web of Science ®Google Scholar
• Ma J, Yang YL, Wang Y, et al. Relationship between computed tomography morphology and prognosis of patients with stage I non-small cell lung cancer. Onco Targets Ther. 2017;10:2249–2256. doi:10.2147/OTT.S11496028461759
   PubMed Web of Science ®Google Scholar
• Choi CM, Kim MY, Lee JC, et al. Advanced lung adenocarcinoma harboring a mutation of the epidermal growth factor receptor: CT findings after tyrosine kinase inhibitor therapy. Radiology. 2014;270(2):574–582. doi:10.1148/radiol.1312182424086072
   PubMed Web of Science ®Google Scholar
• Minemura H, Moriya H, Imai H, et al. Prognostic value of morphological characteristics assessed by CT scan in patients with non‐small cell lung cancer treated with nivolumab. Thorac Cancer. 2020;11(12):3521–3527. doi:10.1111/1759-7714.1369533044045
   PubMed Web of Science ®Google Scholar
• Xu Y, Hosny A, Zeleznik R, et al. Deep learning predicts lung cancer treatment response from serial medical imaging. Clin Cancer Res. 2019;25(11):3266–3275. doi:10.1158/1078-0432.CCR-18-249531010833
   PubMed Web of Science ®Google Scholar
• Miyawaki T, Kenmotsu H, Mori K, et al. Association between clinical tumor burden and efficacy of immune checkpoint inhibitor monotherapy for advanced non-small-cell lung cancer. Clin Lung Cancer. 2020;21(5):e405–e414. doi:10.1016/j.cllc.2020.02.01232205040
   PubMed Web of Science ®Google Scholar
• Galdiero MR, Marone G, Mantovani A. Cancer inflammation and cytokines. Csh Perspect Biol. 2018;10(8):a28662.
   PubMed Web of Science ®Google Scholar
• Diakos CI, Charles KA, McMillan DC, et al. Cancer-related inflammation and treatment effectiveness. Lancet Oncol. 2014;15(11):e493–e503. doi:10.1016/S1470-2045(14)70263-325281468
   PubMed Web of Science ®Google Scholar
• Greten FR, Grivennikov SI. Inflammation and cancer: triggers, mechanisms, and consequences. Immunity. 2019;51(1):27–41.31315034
   PubMed Web of Science ®Google Scholar
• Pavan A, Calvetti L, Dal Maso A, et al. Peripheral blood markers identify risk of immune-related toxicity in advanced non-small cell lung cancer treated with immune-checkpoint inhibitors. Oncologist. 2019;24(8):1128–1136. doi:10.1634/theoncologist.2018-056331015312
   PubMed Web of Science ®Google Scholar
• Duchemann B, Remon J, Naigeon M, et al. Integrating circulating biomarkers in the immune checkpoint inhibitor treatment in lung cancer. Cancers. 2020;12(12):3625. doi:10.3390/cancers12123625
   PubMed Web of Science ®Google Scholar
• Gürel D, Ulukuş Ç, Karaçam V, et al. The prognostic value of morphologic findings for lung squamous cell carcinoma patients. Pathology Res Practice. 2016;212(1):1–9. doi:10.1016/j.prp.2015.10.006
   PubMed Web of Science ®Google Scholar
• Chen S, Gao C, Du Q, et al. A prognostic model for elderly patients with squamous non-small cell lung cancer: a population-based study. J Transl Med. 2020;18(1). doi:10.1186/s12967-020-02606-3
   Web of Science ®Google Scholar
• Koike Y, Aokage K, Ikeda K, et al. Machine learning-based histological classification that predicts recurrence of peripheral lung squamous cell carcinoma. Lung Cancer. 2020;147:252–258. doi:10.1016/j.lungcan.2020.07.01132763506
   PubMed Web of Science ®Google Scholar
• Park SY, Lee H, Jang H, et al. Tumor necrosis as a prognostic factor for stage IA non-small cell lung cancer. Ann Thorac Surg. 2011;91(6):1668–1673. doi:10.1016/j.athoracsur.2010.12.02821619963
   PubMed Web of Science ®Google Scholar